Loading
A phase 3 trial of Tisagenlecleucel in diffuse large b-cell lymphoma, run by Novartis Pharmaceuticals, now recruiting.
Study of Out of Specification for Tisagenlecleucel is a phase 3 interventional study registered as NCT04094311 by Novartis Pharmaceuticals, with 200 participants planned, started 2019-11-21 and due to reach its primary completion in 2027-03-31. Interventions recorded: CTL019. Conditions listed: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Tisagenlecleucel, Novartis, CAR-T cell therapy.
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Tisagenlecleucel, Novartis, CAR-T cell therapy.
Shares Novartis, Diffuse large B-cell lymphoma.